GlassScriptPhysician profile
Amanda Kassab
NPI 1760188312
$1,780.06
in general payments reported to CMS, 2019-2025
16 companies · $984 in 2025
The $984 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $390 · 2024: $407 · 2025: $984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,780.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $777.83 | 2024-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $236.61 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Verona Pharma, INC. | $204.22 | 2025 | Ohtuvayre |
| Ironwood Pharmaceuticals, INC | $98.58 | 2023-2024 | Linzess |
| Otsuka America Pharmaceutical, INC. | $85.05 | 2023-2024 | Rexulti |
| Lilly USA, LLC | $69.14 | 2023-2025 | Mounjaro, Trulicity, Jardiance |
| Lundbeck LLC | $60.18 | 2024-2025 | Rexulti |
| Abbvie INC. | $60.00 | 2023-2024 | |
| Pfizer INC. | $42.57 | 2023-2024 | |
| Alkermes, INC. | $33.16 | 2025 | Lybalvi |
| Axsome Therapeutics, INC. | $21.92 | 2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.61 | 2025 | Caplyta |
| Novo Nordisk INC | $20.31 | 2025 | Wegovy |
| Indivior INC. | $18.42 | 2024 | Sublocade |
| Orexo US, INC. | $17.42 | 2025 | Zubsolv |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $14.04 | 2024 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Kassab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.